Controlled Substances Market

Controlled Substances Market Analysis by Opioids, Stimulants, Depressants, and Marijuana for ADHD, Pain Management, Depression, Seizures, and Anxiety from 2023 to 2033

Analysis of Controlled Substances Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Controlled Substances Market Overview (2023 to 2033)

The global controlled substances market size is estimated at US$ 85.2 Billion in 2023, and is expected to attain a valuation of US$ 139 Billion by 2033-end, growing at a Compound Annual Growth Rate (CAGR) of 5% during the forecast period from 2023 to 2033.

Controlled substances are usually drugs whose manufacturing, distribution, and possession are regulated by governments as they may have the potential to cause addiction or result in substance abuse. Usually, controlled substances are distributed through prescriptions given out by medical professionals for the treatment of various mental and physical health disorders.

Storing controlled drugs illegally and distributing them without prescriptions could result in legal action in almost all countries around the world, with penalties varying from cash fines to imprisonment. The surging use of controlled substances to treat various medical conditions and their rising use in drug development and drug formulation procedures is also expected to boost market growth across the forecast period.

Rising number of people opting for medical marijuana over prescription drugs for the treatment of mental and physical health conditions is also projected to uplift shipments of controlled substances over the next ten years. Moreover, rising investments in medical research and development activities are also slated to benefit market development going forward.

Increasing prevalence of chronic health disorders, growing awareness regarding the benefits of controlled substances, rising demand for alternative medicine, and growing popularity of electronic prescriptions for controlled substances are also projected to incite market growth in the long run.

On the contrary, the soaring use of controlled substances in the manufacturing of illicit drugs and trafficking of controlled medications are major issues that are plaguing the medical industry for years and are projected to hamper controlled substance sales in the future.

  • In May 2022, CVS Health Corp. and Walmart Inc., announced that they would stop selling prescriptions for controlled substances issued by telehealth start-ups such as Done Health and Cerebral Inc. Walmart stated that the decision was made after an audit and compliance process regarding the prescription of controlled substances.

An assessment expanding your knowledge on market influencing aspects such as supply chain management, local supply, product standards, safety regulations, and other market trends has been mentioned listed in this controlled substances market research survey by Fact.MR, a market research and competitive intelligence provider.

Report Attributes Details
Market Size (2023) US$ 85.2 Billion
Projected Market Value (2033F) US$ 139 Billion
Global Market Growth Rate (2023 to 2033) 5% CAGR
Market Share of North America (2022) ~35%
Key Companies Profiled GlaxoSmithKline Plc; SAFC/Cerilliant; AMRI; Mallinckrodt plc; GW PHARMACEUTICALS PLC; Takeda Pharmaceutical Company Limited; Noramco Inc.; Teva Pharmaceuticals Inc.; Johnson Matthey; Siegfried AG; Cayman Chemical; Consort Medical; Patheon; Canopy Growth Corporation; Cambrex; Pfizer Inc.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Start-ups are Altering the Future of Controlled Substance Sales?

“Cerebral and Done Global Inc. to Crucially Influence Future of Controlled Substance Vendors”

Telehealth start-ups picked up traction with the advent of the global COVID-19 pandemic that started in early 2020 and online prescriptions were made legal in several countries. This trend continued even after the pandemic situation subsided and this create an opportune scenario for new companies to roll out their telehealth and online consultation services.

  • Cerebral, a mental health start-up founded in 2019, was being investigated by the United States Department of Justice for the prescription of controlled substances such as Xanax and Adderall. The company offers therapy and prescribes treatment for conditions such as insomnia, ADHD, anxiety, etc. The investigation is an ongoing affair since 2022 and also resulted in the company halting the issuing of prescriptions for controlled medications for its new patients.
  • In September 2022, reports were surfacing that the Drug Enforcement Administration’s Diversion Control Division is investigating Done Global Inc., a virtual ADHD medication management start-up. However, a company official came out and stated that the company had not received any notification from the DEA or any other federal organization for the same.

The crackdown on telehealth and virtual health start-ups that began with Cerebral is now affecting demand and sales of controlled substances around the world. Adderall is a major controlled substance that has been causing issues since it has the potential for drug abuse and possible dependence.

Federal laws and regulatory mandates surrounding the distribution and use of controlled substances are anticipated to create obstacles for incoming controlled substance providers and also hamper the business potential of established controlled substance companies.

Country-wise Insights

How is the Market for Controlled Substances Faring in the United States?

“Surging Use of Controlled Substances for Treatment of Diseases”

The use of controlled substances is relatively high in the United States as compared to most of the other countries in the world. Being a leader in pharmaceutical manufacturing and having a robust healthcare infrastructure has made the country a highly attractive market for controlled substance manufacturers and suppliers alike.

Rising number of patients using opioids and other controlled medications for the treatment of several health conditions is also projected to open up new avenues of opportunity for controlled substance companies in the United States going forward. Moreover, the legalization of medical marijuana in several states of the country is also expected to uplift market development across the forecast period.

On the flip side, the presence of controlled medication trafficking and substance abuse problems in American society is expected to foil controlled substance shipments in the future.

Why Should Controlled Substance Producers Invest in Japan?

“Expanding Senescent Population and Rising Focus on Healthcare”

Investments in healthcare infrastructure development have been increasing in Japan just like most other Asian countries in the region and this is creating moneymaking opportunities for controlled substance suppliers. The Japanese government is taking steps to strengthen its healthcare infrastructure which has been under pressure owing to the rising aging population in the country.

Growing prevalence of cancer and other chronic diseases is also a factor that is projected to promulgate sales of controlled substances in Japan over the next ten years. Drug pricing in the country is controlled by its government and this is also a key factor that could alter the demand for controlled substances across the forecast period in Japan. The rising popularity of generic medications in Japan could pave the way for new drugs and medications formulated using controlled substances.

Why Could European Countries Witness High Demand for Controlled Substances in the Future?

“Germany, France, & United Kingdom to Lead Product Demand in Europe”

The approval process for new drug formulations and medications has been changing in several European countries and this is projected to uplift the demand for controlled substances in Europe going forward. Furthermore, the relaxation of prescription policies in European countries is also anticipated to promulgate sales of controlled substances over the next ten years.

Increasing geriatric population, rising investments from public and private sectors in medical R&D, rising healthcare expenditure, growing demand for alternative medicines, surging prevalence of chronic disorders, and increasing use of controlled medications for the treatment of chronic diseases are other factors that influence shipments of controlled substances in countries such as Germany, France, Italy, and the United Kingdom.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Category-wise Insights

Which Drug Class Accounts for a Commanding Market Share?

“Opioids Leading Global Market Growth”

Based on drug class, the market for controlled substances is segmented into opioids, depressants, stimulants, and marijuana.

Opioids account for a substantial share of the global controlled substances marketplace at present and are estimated to maintain a similar stance throughout the forecast period. They are extensively used in cancer treatment as they have pain-relieving abilities. The growing incidence of different types of cancers around the world is expected to boost the demand for opioids over the next ten years.

But the use of opioids is expected to be reduced in the long term owing its addiction issues that are increasing among patients around the world. Substance abuse through opioid drugs is a concerning factor that is projected to hamper sales of opioids across the forecast period.

Competitive Landscape

Prime controlled substance manufacturers are focusing on launching new products that help them maximize their business potential and gain a competitive advantage over other market players.

  • In February 2023, Eighty Six, a provider of products derived from cannabinoids, announced its entry into the legal psychedelics marketplace with the launch of its new gummies under the name Fun Guy. The gummies are made from Amanita mushrooms that are legal through a loophole in all states of the United States except Louisiana.

More insights about new developments by leading controlled substance vendors and how they alter future pricing trends and product standards have been extensively discussed in this Fact.MR research survey.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Key Segments of Controlled Substances Industry Research

  • By Drug Class :

    • Opioids
      • Codeine
      • Morphine
      • Fentanyl
      • Meperidine
      • Methadone
      • Oxycodone
      • Others
    • Stimulants
      • Amphetamine
      • Methylphenidate
      • Dextroamphetamine
      • Methamphetamine
      • Others
    • Depressants
      • Barbiturates
      • Benzodiazepines
    • Marijuana
      • Medical Marijuana
      • Recreational Marijuana

  • By Application :

    • Attention-Deficit/Hyperactivity Disorder (ADHD)
    • Pain Management
    • Depression
    • Seizure
    • Anxiety
    • Sleep Disorders
    • Cough Suppression
    • Others

  • By Distribution Channel :

    • Institutional Sales
      • Hospitals
      • Clinics
      • Rehabilitation Centers
    • Retail Sales
      • Retail Pharmacies
      • e-Commerce/Mail Order Pharmacies

  • By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Table of Content

  • 1. Executive Summary
  • 2. Market Overview
  • 3. Key Market Trends
  • 4. Key Success Factors
  • 5. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018 to 2022 and Forecast, 2023 to 2033
  • 6. Market Background
  • 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Drug Class
    • 7.1. Opioids
      • 7.1.1. Codeine
      • 7.1.2. Morphine
      • 7.1.3. Fentanyl
      • 7.1.4. Meperidine
      • 7.1.5. Methadone
      • 7.1.6. Oxycodone
      • 7.1.7. Others
    • 7.2. Stimulants
      • 7.2.1. Amphetamine
      • 7.2.2. Methylphenidate
      • 7.2.3. Dextroamphetamine
      • 7.2.4. Methamphetamine
      • 7.2.5. Others
    • 7.3. Depressants
      • 7.3.1. Barbiturates
      • 7.3.2. Benzodiazepines
    • 7.4. Marijuana
      • 7.4.1. Medical Marijuana
      • 7.4.2. Recreational Marijuana
  • 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Application
    • 8.1. Attention-Deficit/Hyperactivity Disorder (ADHD)
    • 8.2. Pain Management
    • 8.3. Depression
    • 8.4. Seizure
    • 8.5. Anxiety
    • 8.6. Sleep Disorders
    • 8.7. Cough Suppression
    • 8.8. Others
  • 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Distribution Channel
    • 9.1. Institutional Sale
      • 9.1.1. Hospitals
      • 9.1.2. Clinics
      • 9.1.3. Rehabilitation Centers
    • 9.2. Retail Sales
      • 9.2.1. Retail Pharmacies
      • 9.2.2. E-Commerce/Mail Order Pharmacies
  • 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region
    • 10.1. North America
    • 10.2. Latin America
    • 10.3. Europe
    • 10.4. Middle East and Africa (MEA)
    • 10.5. East Asia
    • 10.6. South Asia
    • 10.7. Oceania
  • 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
  • 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
  • 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
  • 14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
  • 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
  • 16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033
  • 17. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
  • 18. Emerging Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033
  • 19. Competition Analysis
    • 19.1. Cambrex
    • 19.2. Patheon
    • 19.3. Consort Medical
    • 19.4. Cayman Chemical
    • 19.5. AMRI
    • 19.6. Siegfried AG
    • 19.7. Johnson Matthey
    • 19.8. SAFC/Cerilliant
    • 19.9. Noramco, Inc
    • 19.10. Mallinckrodt plc
    • 19.11. GlaxoSmithKline plc.
    • 19.12. Purdue Pharma L.P.
    • 19.13. Teva Pharmaceuticals, Inc.
    • 19.14. Johnson & Johnson (Janssen)
    • 19.15. Daiichi Sankyo Company
    • 19.16. Akorn Inc
    • 19.17. Pfizer Inc.
    • 19.18. Takeda Pharmaceutical Company Limited
    • 19.19. Mylan N.V.
    • 19.20. Sun Pharmaceutical Industries Ltd
    • 19.21. Tilray
    • 19.22. GW PHARMACEUTICALS PLC
    • 19.23. Aphria Incorporation
    • 19.24. Aurora Cannabis Inc
    • 19.25. Canopy Growth Corporation
    • 19.26. Insys Therapeutics, Inc.
    • 19.27. Medical Marijuana, Inc.
    • 19.28. The Peace Naturals Project
    • 19.29. CANNABIS SATIVA, INC.
    • 19.30. Green Relief Inc.
  • 20. Assumptions and Acronyms Used
  • 21. Research Methodology

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Pipeline Assessment for Stimulants

Table 02: Expenditure on Health, (% of GDP), by Country, 2018 to 2022

Table 03: Expenditure on Health, (% of GDP), by Country, 2018 to 2022

Table 04: Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 05: Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 06: Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 07: Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 08: Global Market size (US$ Mn) Analysis 2013 to 2017 and Forecast 2018 to 2028 By Region

Table 09: North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 10: North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 11: North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 12: North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 13: North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 14: Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 15: Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 16: Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 17: Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 18: Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 19: Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 20: Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 21: Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 22: Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 23: Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 24: East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 25: East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 26: East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 27: East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 28: East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 29: South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 30: South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 31: South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 32: South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 33: South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 34: Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 35: Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 36: Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 37: Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 38: Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 39: MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

Table 40: MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 41: MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 42: MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 43: MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 44: Emerging Market Value Proportion Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country vs Global value

Table 45: India Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 46: India Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 47: India Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 48: India Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 49: South Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 50: South Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 51: South Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 52: South Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

Table 53: Brazil Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 54: Brazil Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

Table 55: Brazil Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

Table 56: Brazil Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Pipeline Assessment For Opioids, By phase

Figure 02: Pipeline Assessment For Opioids, By Trial Status

Figure 03: Pipeline Assessment For Stimulants, By phase

Figure 04: Pipeline Assessment For Stimulants, By Trial Status

Figure 05: Medical Marijuana Patent Citations Analysis, 2018 to 2022, By Country

Figure 06: Medical Marijuana Patent Citations Analysis, from 2023 to 2033

Figure 07: Global Market Value Analysis and Forecast, 2018 to 2033 (US$ Mn)

Figure 08: Global Market Absolute $ Opportunity (US$ Mn), 2018 to 2022

Figure 09: Global Market Absolute $ Opportunity (US$ Mn), 2018 to 2033

Figure 10: Global Market Share%, by Drug Class, 2022E - Opioids

Figure 11: Global Market Share%, by Drug Class, 2022E - Stimulants

Figure 12: Global Market Share%, by Drug Class, 2022E - Depressants

Figure 13: Global Market Share%, by Drug Class, 2022E - Marijuana

Figure 14: Global Market Size (US$ Mn) Analysis, 2018 to 2022, by Opioids

Figure 15: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Opioids

Figure 16: Global Market Size (US$ Mn) Analysis, 2018 to 2022, by Stimulants

Figure 17: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Stimulants

Figure 18: Global Market Size (US$ Mn) Analysis, 2018 to 2022, by Depressants

Figure 19: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Depressants

Figure 20: Global Market Size (US$ Mn) Analysis, 2018 to 2022, by Marijuana

Figure 21: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Marijuana

Figure 22: Global Market Attractiveness Analysis, By Drug Class

Figure 23: Global Market Attractiveness Analysis, By Application

Figure 24: Global Market Attractiveness Analysis, By Distribution Channel

Figure 25: Global Market Incremental Opportunity US$, by Region, 2018 to 2033

Figure 26: Market Share%, by Region, 2022E

Figure 27: Global Market Absolute Opportunity US$, by Region, 2023 to 2033

Figure 28: Market Share%, by Region, 2033F

Figure 29: Global Market Attractiveness Analysis, By Region

Figure 30: North America Market size (US$ Mn) Analysis, 2018 to 2022

Figure 31: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 32: US Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 33: US Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 34: Canada Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 35: Canada Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 36: North America Market Size (US$ Mn) Analysis, 2018 to 2022, by Opioids

Figure 37: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Opioids

Figure 38: North America Market Size (US$ Mn) Analysis, 2018 to 2022, by Stimulants

Figure 39: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Stimulants

Figure 40: North America Market Size (US$ Mn) Analysis, 2018 to 2022, by Depressants

Figure 41: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Depressants

Figure 42: North America Market Size (US$ Mn) Analysis, 2018 to 2022, by Marijuana

Figure 43: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Marijuana

Figure 44: North America Market Attractiveness Analysis, By Drug Type

Figure 45: North America Market Attractiveness Analysis, By Application

Figure 46: North America Market Attractiveness Analysis, By Distribution Channel

Figure 47: North America Market Attractiveness Analysis, By Country

Figure 48: Latin America Market size (US$ Mn) Analysis, 2018 to 2022

Figure 49: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 50: Brazil Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 51: Brazil Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 52: Mexico Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 53: Mexico Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 54: Rest of Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 55: Rest of Latin America Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 56: Latin America Market Size (US$ Mn) Analysis, 2018 to 2022, by Opioids

Figure 57: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Opioids

Figure 58: Latin America Market Size (US$ Mn) Analysis, 2018 to 2022, by Stimulants

Figure 59: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Stimulants

Figure 60: Latin America Market Size (US$ Mn) Analysis, 2018 to 2022, by Depressants

Figure 61: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Depressants

Figure 62: Latin America Market Size (US$ Mn) Analysis, 2018 to 2022, by Marijuana

Figure 63: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Marijuana

Figure 64: Latin America Market Attractiveness Analysis, By Drug Type

Figure 65: Latin America Market Attractiveness Analysis, By Application

Figure 66: Latin America Market Attractiveness Analysis, By Distribution Channel

Figure 67: Latin America Market Attractiveness Analysis, By Country

Figure 68: Europe Market size (US$ Mn) Analysis, 2018 to 2022

Figure 69: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 70: U.K. Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 71: U.K. Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 72: Germany Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 73: Germany Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 74: France Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 75: France Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 76: Italy Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 77: Italy Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 78: Spain Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 79: Spain Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 80: BENELUX Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 81: BENELUX Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 82: Russia Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 83: Russia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 84: Rest of Europe Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 85: Rest of Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 86: Europe Market Size (US$ Mn) Analysis, 2018 to 2022, by Opioids

Figure 87: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Opioids

Figure 88: Europe Market Size (US$ Mn) Analysis, 2018 to 2022, by Stimulants

Figure 89: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Stimulants

Figure 90: Europe Market Size (US$ Mn) Analysis, 2018 to 2022, by Depressants

Figure 91: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Depressants

Figure 92: Europe Market Size (US$ Mn) Analysis, 2018 to 2022, by Marijuana

Figure 93: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Marijuana

Figure 94: Europe Market Attractiveness Analysis, By Drug Type

Figure 95: Europe Market Attractiveness Analysis, By Application

Figure 96: Europe Market Attractiveness Analysis, By Distribution Channel

Figure 97: Europe Market Attractiveness Analysis, By Country

Figure 98: East Asia Market size (US$ Mn) Analysis, 2018 to 2022

Figure 99: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 100: China Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 101: China Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 102: Japan Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 103: Japan Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 104: South Korea Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 105: South Korea Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 106: East Asia Market Size (US$ Mn) Analysis, 2018 to 2022, by Opioids

Figure 107: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Opioids

Figure 108: East Asia Market Size (US$ Mn) Analysis, 2018 to 2022, by Stimulants

Figure 109: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Stimulants

Figure 110: East Asia Market Size (US$ Mn) Analysis, 2018 to 2022, by Depressants

Figure 111: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Depressants

Figure 112: East Asia Market Size (US$ Mn) Analysis, 2018 to 2022, by Marijuana

Figure 113: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Marijuana

Figure 114: East Asia Market Attractiveness Analysis, By Drug Type

Figure 115: East Asia Market Attractiveness Analysis, By Application

Figure 116: East Asia Market Attractiveness Analysis, By Distribution Channel

Figure 117: East Asia Market Attractiveness Analysis, By Country

Figure 118: South Asia Market size (US$ Mn) Analysis, 2018 to 2022

Figure 119: Global Donor Egg IVF Market Attractiveness Analysis by Region , 2023 to 2033

Figure 119: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 120: India Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 121: India Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 122: Thailand Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 123: Thailand Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 124: Indonesia Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 125: Indonesia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 126: Malaysia Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 127: Malaysia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 128: Rest of South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 129: Rest of South Asia Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 130: South Asia Market Size (US$ Mn) Analysis, 2018 to 2022, by Opioids

Figure 131: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Opioids

Figure 132: South Asia Market Size (US$ Mn) Analysis, 2018 to 2022, by Stimulants

Figure 133: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Stimulants

Figure 134: South Asia Market Size (US$ Mn) Analysis, 2018 to 2022, by Depressants

Figure 135: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Depressants

Figure 136: South Asia Market Size (US$ Mn) Analysis, 2018 to 2022, by Marijuana

Figure 137: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Marijuana

Figure 138: South Asia Market Attractiveness Analysis, By Drug Type

Figure 139: South Asia Market Attractiveness Analysis, By Application

Figure 140: South Asia Market Attractiveness Analysis, By Distribution Channel

Figure 141: South Asia Market Attractiveness Analysis, By Country

Figure 142: Oceania Market size (US$ Mn) Analysis, 2018 to 2022

Figure 143: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 144: Australia Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 145: Australia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 146: New Zealand Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 147: New Zealand Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 148: Oceania Market Size (US$ Mn) Analysis, 2018 to 2022, by Opioids

Figure 149: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Opioids

Figure 150: Oceania Market Size (US$ Mn) Analysis, 2018 to 2022, by Stimulants

Figure 151: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Stimulants

Figure 152: Oceania Market Size (US$ Mn) Analysis, 2018 to 2022, by Depressants

Figure 153: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Depressants

Figure 154: Oceania Market Size (US$ Mn) Analysis, 2018 to 2022, by Marijuana

Figure 155: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Marijuana

Figure 156: Oceania Market Attractiveness Analysis, By Drug Type

Figure 157: Oceania Market Attractiveness Analysis, By Application

Figure 158: Oceania Market Attractiveness Analysis, By Distribution Channel

Figure 159: Oceania Market Attractiveness Analysis, By Country

Figure 160: MEA Market size (US$ Mn) Analysis, 2018 to 2022

Figure 161: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 162: South Africa Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 163: South Africa Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 164: GCC Countries Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 165: GCC Countries Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 166: Rest of MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 167: Rest of MEA Market Size (US$ Mn) Analysis, 2018 to 2022

Figure 168: MEA Market Size (US$ Mn) Analysis, 2018 to 2022, by Opioids

Figure 169: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Opioids

Figure 170: MEA Market Size (US$ Mn) Analysis, 2018 to 2022, by Stimulants

Figure 171: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Stimulants

Figure 172: MEA Market Size (US$ Mn) Analysis, 2018 to 2022, by Depressants

Figure 173: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Depressants

Figure 174: MEA Market Size (US$ Mn) Analysis, 2018 to 2022, by Marijuana

Figure 175: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033, by Marijuana

Figure 176: MEA Market Attractiveness Analysis, By Drug Type

Figure 177: MEA Market Attractiveness Analysis, By Application

Figure 178: MEA Market Attractiveness Analysis, By Distribution Channel

Figure 179: MEA Market Attractiveness Analysis, By Country

Figure 180: Market Value Proportion Analysis, By Key Countries, 2022E

Figure 181: Global Vs. Country, Y-O-Y Growth Comparison

Figure 182: India Market size (US$ Mn) Analysis, 2018 to 2022

Figure 183: India Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 184: India Market Attractiveness Analysis, By Drug Class

Figure 185: India Market Attractiveness Analysis, By Application

Figure 186: India Market Attractiveness Analysis, By Distribution Channel

Figure 187: South Africa Market size (US$ Mn) Analysis, 2018 to 2022

Figure 188: South Africa Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 189: South Africa Market Attractiveness Analysis, By Drug Class

Figure 190: South Africa Market Attractiveness Analysis, By Application

Figure 191: South Africa Market Attractiveness Analysis, By Distribution Channel

Figure 192: Brazil Market size (US$ Mn) Analysis, 2018 to 2022

Figure 193: Brazil Market Value (US$ Mn) & Y-o-Y Growth (%), 2023 to 2033

Figure 194: Brazil Market Attractiveness Analysis, By Drug Class

Figure 195: Brazil Market Attractiveness Analysis, By Application

Figure 196: Brazil Market Attractiveness Analysis, By Distribution Channel

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

What is the total market worth of the controlled substances market?

The global controlled substances market is valued at US$ 85.2 billion in 2023.

What is the projected controlled substances market size for 2033?

Worldwide controlled substance sales are expected to reach US$ 139 billion by 2033-end.

What is the growth rate of the global controlled substances market?

From 2023 to 2033, consumption of controlled substances is expected to rise steadily at 5% CAGR.

What are the 4 types of controlled substances?

Opioids, depressants, stimulants, and marijuana are the types of controlled substances detailed in this report.

What are the driving factors of the controlled substances market?

Rising use of opioids in cancer treatment and increasing investments in medical research & development are key market drivers.

Who are the key players in the controlled substances market?

Johnson Matthey, Siegfried AG, Cayman Chemical, Consort Medical, and Patheon are leading suppliers of controlled substances.

Controlled Substances Market

Schedule a Call

Copyright © Fact.MR All Rights Reserved

An initiative of Eminent Research and Advisory Services